Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gentium S.p.A.

http://www.gentium.it/

Latest From Gentium S.p.A.

Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m

Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.

Deal Watch Business Strategies

EU: Doctors Told Not To Use Defitelio As A Prophylactic For VOD

While Defitelio is not authorized in the EU for the prevention of veno-occlusive disease (VOD), the European Medicines Agency wants health professionals to be informed about the results of a recent study in which the drug showed no benefit in this indication.

Liver & Hepatic Risk Management

Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition

AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.

Deal Watch Business Strategies

Lilly Supports RNA R&D Push With $700m Investment In Institute For Genetic Medicine

The big pharma has a gene therapy R&D site in New York from its Prevail Therapeutics buy; the RNA-focused Boston site also will conduct drug delivery research benefitting programs at both locations.

Innovation Strategy
See All

Company Information

UsernamePublicRestriction

Register